(Q34020127)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21920036%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

editorial

0 references

title

5-α reductase inhibitors and prostate cancer prevention: where do we turn now? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21920036%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

Robert James Hamilton

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21920036%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Stephen J Freedland

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21920036%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

language of work or name

English

0 references

publication date

15 September 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21920036%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21920036%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21920036%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

105

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21920036%20AND%20SRC:MED&resulttype=core&format=json

Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study

12 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180399

Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180399

Cost utility of prostate cancer chemoprevention with dutasteride in men with an elevated prostate specific antigen

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180399

Impact of Common Medications on Serum Total Prostate-Specific Antigen Levels: Analysis of the National Health and Nutrition Examination Survey

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180399

Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180399

Prostate cancer prevention: concepts and clinical recommendations

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180399

Effect of dutasteride on the risk of prostate cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180399

Long-term medical-care costs related to prostate cancer: estimates from linked SEER-Medicare data

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180399

Cost effectiveness of 5-alpha reductase inhibitors for the prevention of prostate cancer in multiple patient populations

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180399

Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated?

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180399

Time trends and local variation in primary treatment of localized prostate cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180399

The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180399

Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180399

Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180399

Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180399

Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180399

20-year outcomes following conservative management of clinically localized prostate cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180399

The influence of finasteride on the development of prostate cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180399

Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180399

Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

28 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-105

The influence of statin medications on prostate-specific antigen levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-105

Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-105

Statin use and risk of prostate cancer recurrence in men treated with radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-105

Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-105

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-105

Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and T

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-105

5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-105

Predicting 15-year prostate cancer specific mortality after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-105

Evidence for a biopsy derived grade artifact among larger prostate glands

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-105

Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-105

Knowledge and use of finasteride for the prevention of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-105

Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-105

Do the benefits of finasteride outweigh the risks in the prostate cancer prevention trial?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-9-105

Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180399

Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3180399

Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial

29 October 2018

1 reference

12 December 2020

The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups

1 reference

12 December 2020

Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial

1 reference

12 December 2020

Endocrine dependence of prostatic cancer upon dihydrotestosterone and not upon testosterone

1 reference

12 December 2020

Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer

1 reference

12 December 2020

Prostate Cancer and Supplementation With α-Tocopherol and β-Carotene: Incidence and Mortality in a Controlled Trial

1 reference

12 December 2020

Effect of Finasteride on the Sensitivity of PSA for Detecting Prostate Cancer

1 reference

12 December 2020

Identifiers

DOI

10.1186/1741-7015-9-105

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21920036%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

12 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21920036%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

PubMed publication ID

21920036

1 reference